Abstract Library

#4291 Novel genomic score predicts survival with immune checkpoint blockade in neuroendocrine neoplasms

Introduction: Immune checkpoint inhibition (ICI) has activity in Grade 3 (G3) neuroendocrine neoplasms (NENs) but predictive biomarkers of overall survival (OS) are currently lacking.

Conference:

Presenting Author:

Authors: Brar T, Sukrithan V, Le D, Xu M, Olowookere C,

Keywords: Neuroendocrine Neoplasm, Immunotherapy, Ipilimumab, Nivolumab, Immune checkpoint inhibitor, biomarker, genomic score,

#4068 YAP-1 as prognostic marker for immunochemotherapy response in SCLC patients

Introduction: Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is an exceptionally lethal malignancy for which more effective therapies are urgently needed. Previous studies have classified SCLC patients by RNA-sequencing (RNA-seq) clustering analysis to identify who could benefit from immune checkpoint blockades.

Conference:

Presenting Author:

Authors: Sabella G,

Keywords: neuroendocrine, immunochemotherapy, SCLC, YAP-1,

#3655 Whole exome sequencing of rectal neuroendocrine tumors

Introduction: The genetic characteristics of rectal neuroendocrine tumors (R-NETs) were poorly understood.

Conference:

Presenting Author:

Authors: Li Y, Guo Y, Cheng Z, Tian C, Chen Y,

Keywords: rectal neuroendocrine tumor, whole exome sequencing, prognosis, targeted therapy, immune checkpoint blockade,

#3391 Final results from the DUNE trial (GETNE 1601): Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins

Introduction: Activity of immune checkpoint blockade in advanced NENs remains controversial.

Conference:

Presenting Author:

Authors: Capdevila J, Teulé A, Hernando J, López C, Garcia-Carbonero R,

Keywords: advanced neuroendocrine neoplasm, Immunotherapy, durvalumab, tremelimumab,

#3195 Peptide Radio Receptor Therapy sensitizes to immunotherapy by increasing expression of checkpoint molecules in in patients with neuroendocrine tumors

Introduction: Peptide Radio Receptor Therapy (PRRT) represents a standard treatment in patients with well-differentiated neuroendocrine tumors (NET G1/G2). Nevertheless, a lack of response is observed in 1/3 of patients after PRRT, suggesting that combination of PRRT with other therapies might increase its efficacy. The combination of PRRT with immune checkpoint inhibitors (ICI) might be promising, since radiation induced cell death can trigger antigen release and lead to activation of the immune system.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hammerich L

Authors: Büttne S, Wiedenmann B, Amthauer H, Tacke F, Roderburg C,

Keywords: neuroendocrine tumor, checkpoint blockade, PRRT, immunotherapy, spectral flow cytometry,